Skip to contentpdufa.bio

casdozokitug

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

casdozokitug is a Coherus Oncology, Inc. program in first-line unresectable hepatocellular carcinoma (1L uHCC). Its next catalyst is a Readout in Q2 2027.

CHRS catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: first-line unresectable hepatocellular carcinoma (1L uHCC). Sponsor: Coherus Oncology, Inc. (CHRS). We track 2 catalyst events for this program: 2 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q2 2027CHRSReadout · Sep 2027CHRS

Questions

When is casdozokitug's next FDA decision or readout?

The next tracked catalyst for casdozokitug is a Readout in Q2 2027.

What happened at casdozokitug's most recent FDA decision?

No FDA decision for casdozokitug is in our archive yet.

What is casdozokitug used for?

In our records casdozokitug is under review or in development for first-line unresectable hepatocellular carcinoma (1L uHCC).

Who makes casdozokitug?

Coherus Oncology, Inc. (CHRS).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.